Last reviewed · How we verify
Novolog
At a glance
| Generic name | Novolog |
|---|---|
| Also known as | insulin, insulin aspart, Insulin Aspart, a rapid-acting human insulin analogue, NovoRapid, NovoLog® |
| Sponsor | Massachusetts General Hospital |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Diabetes mellitus
Common side effects
- Hypoglycemia
- Headache
- Hypoglycemia
- Influenza-like symptoms
- Upper respiratory tract infection
- Dyspepsia
- Headache
- Diarrhea
- Neuropathy
- Diarrhea
- Back pain
- Pharyngitis
Serious adverse events
- Severe hypoglycemia
- Severe hypoglycemia
- Anaphylaxis
- Worsening of diabetic retinopathy
- Acute painful peripheral neuropathy
- Ophthalmologic refraction disorder
- Allergic reactions
- Erythema
- Edema
- Pruritus
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Fiasp® Versus NovoRapid® in Children With Type 1 Diabetes on MiniMed 640G Pump With Sensor
- Two Way Crossover Closed Loop MPC vs Control IQ (NA)
- Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers (PHASE2, PHASE3)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |